A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer

Clinical and Translational Oncology

Volumn 7, Issue 2, 2005, Pages 66-73

  Galcerán, Joan Carles ^a   Piulats, Romà Bastus ^b   Martín Broto, Javier ^c   Rey, Pablo Maroto ^d   Aligué, Miquel Nogué ^e   Santasusana, Montserrat Domenech ^f   Lanza, Angels Arcusa ^g   Molins, Joaquim Bellmunt ^h   Colin, Catherine ⁱ   Girard, Atika ⁱ  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Consorci Hospitalari Parc Tauli de Sabadell ^*  (Spain)

^f Centre Hospitalari Cardiologic de Manresa   (Spain)

^g Hospital General de Terrassa   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Estramustine; Prostate carcinoma; Vinorelbine

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRAMUSTINE; NAVELBINE; VINBLASTINE;

AGED; ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; VINBLASTINE;

EID: 24344456039     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02710012     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. Cancer J Clin. 1998;48 6-29.
2. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol. 1992;23:211.
3. Klein LA. Prostatic carcinoma. N Engl J Med. 1996;300: 26-33.
4. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71:1098-109.
5. Williams G, Kerle DJ, Ware H, et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostate cancer. Br J Urol. 1986;58-45.
6. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose pred-nisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590-7.
7. Fossa SD, Hasbach G, Pans E. Flutamide in hormone resistant prostatic cancer. J Urol. 1990;1411-44.
8. Tannock IF, Osoba D, Stocker MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol. 1996;14:1756-64.
9. Kantoff BPW, Halabi S, Conaway H, et al. Hydrocrotisone with or without mitoxantrone in men with hormone-re-fratory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol. 1999;17:2506-13.
10. Stears ME, Wang M, Tew K, Binder LI. Estramustine binds a MAP-I like protein to inhibit microtubule assembly in vitro and disrupts microtubule organisation in DU 145 cells. J Cell Biol. 1988;107:2647-52.
11. Roth BJ. Combination chemotherapy in advanced prostate cancer: A Silk purse. J Clin Oncol. 1994;12:2001-2.
12. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tu-bulin. Cancer Res. 1993;53:4573-81.
13. Stearns ME, Wang M, Tew K, et al. Estramustine binds to a MAP-1 like to inhibit microtubule assembly in vitro and disrupt microtubule organisation in DU-145 cells. J Cell Biol. 1988;107:2647-56.
14. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoo-sier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999;1:3160-6.
15. Hudes G, Ross E, Roth B, et al. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine based antimicrotubule therapy: Final report of a Hoosier Oncology group and Fox chase Network phase III trial comparing vinblastine plus oral estramustine phosphate [abstract 704]. Am Soc Clin Oncol. 2002;21.
16. Morant R, Hsu-Schmitz SF, Bernhard J, et al Vinorel-bine in androgen-independent metastatic prostatic carcinoma-a phase II study. Eur J Cancer. 2002;38: 1626-32.
17. Oudard S, Caty A, Humblet Y, et al. Phase II study of vi-norelbine in patients with androgen-independent prostate cancer. Ann Oncol. 2001;12:847-52.
18. Field-Jones S, Koletsky A, Wilding G, et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol. 1999;10:1307-10.
19. Perry CM, McTanish D. Estramustine phosphate sodium: a review. Drugs and aging. 1995;7:49-74.
20. Colleoni M, Graiff C, Vicario G, et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol. 1997;20: 383-6.
21. Carles J, Domeneck M, Gelabert-Mas A, et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol. 1998; 37:187-91.
22. Sweeney CJ, Monaco FJ, Jung SH, et al. A phase II Hoosier oncology group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002;13:435-40.
23. Smith DMR, Kaufman D, William O, et al. Vinorelbine and estramustine in androgen independent metastatic prostate cancer. Cancer. 2000;89:1824-8.
24. Hudes GR, Geenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992;10:1754-61.
25. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial endpoint for hormone refractory prostatic cancer. J Urol. 1999;147:931-4.
26. Amato RJ, Ellerhost J, Bui C, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol. 1995;1:168-72.
27. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15:3156-63.
28. Petrylak DP, MacArthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-67
29. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999; 10:33-8.
30. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005-12.
31. Pienta KJ, Redman B, Bandekar R, et al. A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology. 1997;50:401-7
32. Dimopoulos MA, Panopoulos C, Bamia C, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology. 1997;50:754-8.
33. Hernes EH, Fossa SD, Vaage S, et al. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer. 1997;76: 93-9.
34. Culine S, Kattan J, Zanetta S, et al. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol. 1998;21:470-4.
35. Serafini AN, Houston SJ, Resche J, et al. Palliation of pain associated with metastatic bone cancer using sa-marium-153 lesidronam: a double-blind placebo controller clinical trial. J Clin Oncol. 1998;16:1574-81.
36. Savarese D, Taplin ME, Halabi S, et al. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hy-drocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukaemia group B trial 9780. Semin Oncol. 1999;26 5 Suppl 17: 39-44.
37. Sinibaldi VJ, Carducci MA, Laufer M, et al. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol. 1999;26 5 Suppl 17:45-8.
38. Petrylak DP, Shelton GB, England-Oven C, et al. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine in patients with androgen-independent prostate cancer (AIPCA) [abstract 334]. Proc Am Soc Clin Oncol. 2000;19:334a.
39. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in patients with hormone refractory prostate cancer (HRPC): updated preliminary analysis [abstract 1361]. Proc Am Soc Clin Oncol. 2000;19.